CClinicalTrials.gg
CompletedNCT01353443Updated May 23, 2023

Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair

An interventional study of Optilene® Mesh Elastic in Abdominal Aortic Aneurysm, sponsored by Universitätsklinikum Hamburg-Eppendorf. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

AIDA Study is a prospective, multicentre, randomized, controlled clinical investigation with patients undergoing median laparotomy for Abdominal Aortic Aneurysm (AAA) repair.

The primary objective of the clinical investigation is to test the hypothesis that insertion of an Optilene® Mesh Elastic mesh - a monofilament, light-weight, large pore sized, polypropylene mesh manufactured by Aesculap AG - is superior to suturing alone and will reduce the hernia formation rate within the first 2 years.

A reduction from 30% to 10% of the patient population is assumed.

Read the detailed description

One of the late complications of the elective surgery of an Abdominal Aortic Aneurysms (AAA) is the formation of an incisional hernia following the AAA repair.

The high frequency of incisional hernia formation in the AAA patients suggests the presence of a structural defect within the fascia.

As a result of these information and that obtained from a small pilot study using mesh prophylactically in high risk group of patients, the concept of using a mesh prophylactically for AAA repairs seems an area worth further exploration.

Owing to the availability of the new generation of meshes with proven good biocompatibility it would seem that this could be a viable means of reducing the herniation rate and therefore re-operation in this high risk population.

Within the investigation Patients requiring elective surgical repair of an AAA will be randomized in one of the following three different groups:

  • Group A: Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
  • Group B: Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
  • Group C: Monofilament, absorbable MonoMax® suture material will be used for the closure of the abdominal cavity.

A total of 282 patients who meet the eligibility criteria will be entered into the clinical investigation (Group A = 94 patients, Group B = 94 patients and Group C = 94 patients).

All patients will have follow-up clinical visits 2 days after surgery, at day of discharge, at 3, 6, and 12 months and a final visit at 24 months. All patients will be asked to complete the health status patient questionnaire EQ-5D preoperatively and at 3, 6, 12 and 24 months postoperatively. As all patients routinely receive an ultrasound at 3, 6, 12, and 24 months, this information will be used to confirm if a hernia is present.

The primary objective of the clinical investigation is to test the hypothesis that insertion of an Optilene® Mesh Elastic mesh is superior to suturing alone and will reduce the hernia formation rate within the first 2 years.

Secondary objectives include:

  1. Lower herniation rate in the 12 months after mesh implantation in group B as compared to group A
  2. Non-inferiority of MonoMax suture material (group C) in comparison to MonoPlus suture material (group A) concerning the rate of incisional hernia after abdominal wall closure at 3, 6, 12, and 24 months after surgery.
  3. Mean time, in days, to return to normal activities as determined by CRF question (comparison of groups A, B, C).
  4. Mean time, in days, to return to work as determined by CRF question (comparison of groups A, B, C).
  5. Differences in mean patient health status as determined by using a patient questionnaire (EQ-5D) at 3, 6, 12 and 24 months post-operatively; pre-operative baseline will be recorded (groups A-C).
  6. Number of wound complications (groups A-C) as determined by medical assessment post-operatively immediately prior to discharge, and at the clinical visits at 3, 6, 12 and 24 months, including infections, seromas, haematomas, and hernia formation, confirmed by ultrasound examination.
  7. Safety as determined by collection of adverse events in the CRF (groups A-C).
02

Conditions studied

  • Abdominal Aortic Aneurysm

Keywords

  • Abdominal Aortic Aneurysm
  • AAA
03

In context

Aneurysm

960 studies on the registry are indexed under Aneurysm; 175 are open to participants now.

This study's enrollment of 282 is above the median of 72 across 462 interventional studies indexed under Aneurysm.

Browse Aneurysm studies →

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 403 studies on the registry; 83 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male and female patients >18 years of age.
  2. Patients undergoing an elective surgery for AAA repair.
  3. Patients who currently have no malignant disease requiring therapy.
  4. Patients who are able to fulfill all clinical investigation requirements
  5. Patients who have provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who require median laparotomy for AAA repair as an emergency procedure.
  2. Expected length of fascia incision > 30 cm.
  3. Patients with coagulopathy
  4. Patients who have had previous median laparotomy and/or laparotomy crossing the incision necessary for AAA laparotomy.
  5. Patients with current immunosuppressive therapy (>40 mg corticoid/day or azathioprine).
  6. Chemotherapy within the last 4 weeks.
  7. Radiotherapy on the treated region within the last 2 months.
  8. Pregnant and breast-feeding women.
  9. Known allergy against ingredients of the investigational products (polypropylene, poly-4-hydroxybutyrate, polydioxanone).
  10. Patients participating in other investigational drug or medical device studies within the preceding 4 weeks.
  11. Patients with an ongoing medical condition or social reason that may affect their ability to complete the two years follow-up period.
  12. Life expectancy less than 24 months.
  13. Severe psychiatric or neurologic disease.
  14. Lack of compliance.
  15. Drug abuse.
  16. Inability to understand and follow the instructions given by the investigator (e.g. dementia, lack of time, insufficient command of language).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
282 participants (actual)

Study arms

  • No intervention
    Group A

    Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.

  • Other
    Group B

    Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.

    Procedure: Optilene® Mesh Elastic

  • No intervention
    Group C

    Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.

Interventions

  • ProcedureOptilene® Mesh Elastic

    A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.

06

What researchers measure

Primary outcomes

  1. Herniation rate

    As an indicator of efficacy, the reduction of herniation rate will be verified by clinical examination and confirmed by Ultrasound.

    Time frame: 24 months

07

Study locations

9 sites
  • Klinikum Stuttgart - Katharinenhospital (KH)
    Stuttgart, Baden-Wurttemberg 70174, Germany
  • Klinikum Nürnberg Süd
    Nürnberg, Bavaria 90471, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Bavaria 97080, Germany
  • Universitätsklinikum Aachen
    Aachen, North Rhine-Westphalia 52074, Germany
  • Klinikum Bremen-Nord
    Bremen, 28755, Germany
  • University Heart Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Asklepios Klinik Wandsbek
    Hamburg, 22043, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Klinikum Ludwigsburg
    Ludwigsburg, 71640, Germany
08

References and documents

Publications

  • Honig S, Diener H, Kolbel T, Reinpold W, Zapf A, Bibiza-Freiwald E, Debus ES; for AIDA study group. Abdominal incision defect following AAA-surgery (AIDA): 2-year results of prophylactic onlay-mesh augmentation in a multicentre, double-blind, randomised controlled trial. Updates Surg. 2022 Jun;74(3):1105-1116. doi: 10.1007/s13304-021-01125-0. Epub 2021 Jul 21. PubMed 34287760 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01353443
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Aesculap AG
Responsible party
Sponsor
First posted
May 13, 2011
Start date
Feb 2011
Primary completion
Aug 2015
Completion
Sep 2015
Last update
May 23, 2023

Study contacts

Sebastian Debus, Prof. Dr.
principal investigator · University Heart Center Hamburg - Eppendorf

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion